Source comparison
Tesamorelin + Ipamorelin Blend Legal: Comparison
Understanding where the tesamorelin + ipamorelin blend sits within the broader regulatory landscape requires comparing it to other peptide categories and compounding scenarios. The following table outlines the key regulatory differences. FDA-approved single pe
This comparison does not assign a generated winner or score.
- Understanding where the tesamorelin + ipamorelin blend sits within the broader regulatory landscape requires comparing it to other peptide categories and compounding scenarios. The following table outlines the key regulatory differences.
- FDA-approved single peptide (e.g., Egrifta)
- Approved for specific indication
- Prescription from licensed provider, dispensed by licensed pharmacy
- Must be used for labeled or off-label indication with clinical justification
- Low—standard pharmaceutical regulation applies
- Safest regulatory pathway; highest manufacturing oversight
- Compounded single peptide (503A/503B)
- Not FDA-approved as drug product
- Prescription + compounding by licensed 503A/503B pharmacy
- Must meet patient-specific need or commercial unavailability criteria
- Moderate—FDA inspects 503B facilities; state boards regulate 503A
- Legal and widely used; quality depends on pharmacy standards
- Compounded peptide blend (tesamorelin + ipamorelin)
- Not FDA-approved as combination product
- Same as single peptides; no additional regulatory hurdle for combinations
- Moderate—same as single compounded peptides
- Legal under off-label prescribing; clinical evidence supports combination rationale
- Research peptides ('not for human use')
- No FDA review
- Direct purchase from research chemical suppliers
- Marketed explicitly as non-human use; no prescription
- High—FDA targets suppliers making implied human-use claims
- Illegal for human consumption; no quality or purity oversight
- International gray-market peptides
- Direct import without prescription
- Bypasses customs and pharmacy regulations
- High—subject to seizure and legal action
- Illegal; no mechanism for quality verification or sterility
- The comparison table demonstrates that the tesamorelin + ipamorelin blend, when obtained through legitimate compounding pathways, occupies the same legal category as any other compounded medication. The combination itself does not trigger additional regulatory scrutiny—what matters is the source. At Real Peptides, we emphasize research-grade purity and exact amino-acid sequencing for laboratory applications, with every batch synthesized under controlled conditions to guarantee consistency and lab reliability.